In the United States, more people need cataract surgery because the population is getting older. Millions of patients need regular checks after surgery to see how they are healing. These follow-ups usually happen a few weeks after surgery. Doctors check for symptoms like pain, changes in vision, or signs of infection. Before, nurses or doctors called or saw patients in person to check up on them. This takes a lot of time and can cause delays.
There are not enough clinical staff, and many are tired from working too much. This makes the problems worse. As more patients need care, it is harder for hospitals to manage with fewer workers. To fix this, some are using AI clinical assistants to make follow-ups easier. These AI helpers can handle simple tasks so doctors have more time for difficult cases.
Autonomous AI clinical assistants are computer programs that can talk to patients using natural speech. This often happens over the phone or by voice. The AI uses special computer programs called machine learning and natural language processing to find symptoms, ask questions, and decide if a patient needs to see a doctor or can be okay on their own.
One example is Dora R1, an AI created by Ufonia Limited. It has been tested in hospitals in the UK. Dora R1 makes follow-up calls to cataract patients about three weeks after surgery. Eye doctors watch these calls live to make sure everything is safe.
A study with over 200 cataract patients in two UK hospitals checked how accurate and safe Dora R1 is. The AI correctly identified patients needing extra care 94% of the time. It also correctly ruled out those who did not need care 86% of the time. Sensitivity means spotting patients who need help, and specificity means not bothering those who do not.
The AI and the human doctors agreed a lot in their decisions, with scores close to perfect in some tests. This shows the AI can work well with doctors.
Safety was also very important. About 9% of patients the AI said were fine to leave later had some changes in their care, but the eye doctors agreed those patients were okay. Four patients that AI said were fine but doctors did not clear did not need extra care afterward. This suggests the AI follow-ups did not miss serious problems and kept patients safe.
Dora R1 finished 96.5% of follow-up calls by itself without needing a person, showing it is very possible to use this system in real hospitals.
Besides accuracy and safety, patients’ feelings about AI follow-ups are important. Studies with patient interviews showed many patients liked the convenience of automated calls. These calls helped patients manage their care without going to a clinic.
Some patients worried about not having a real person to talk to during follow-ups, especially if their cases were complicated or personal. They preferred talking to a doctor. This shows it is good to have a mix of AI handling easy cases and doctors helping with tougher ones.
Medical managers in the United States should think about how to keep human contact available when patients need it.
Using AI assistants like Dora R1 can save money. In the UK study, it saved about £35.18 per patient compared to regular care where doctors make the follow-up calls. This is because the AI reduces the time doctors spend on phone calls.
These savings matter in the US, where healthcare costs are high and insurance favors efficient, value-based care. Automating routine calls lowers staffing needs and lets eye clinics use their resources better while still giving good care.
IT managers and hospital leaders can see clear financial benefits from using these AI systems because they reduce costs and improve how work flows.
Optimizing Clinical Workflows with AI Automation
Besides making calls by itself, AI clinical assistants help improve hospital work. They can connect with electronic health record (EHR) systems, scheduling software, and patient management tools. This helps staff and patients communicate better.
This helps reduce paperwork and makes it easier for busy eye clinics to work smoothly.
Considerations for US Healthcare Providers
In the US, AI tools must follow HIPAA rules to keep patient data private and safe. AI companies like Simbo AI offer systems made to meet these rules, which is very important for hospitals.
Healthcare managers should check if the AI works well with popular EHRs like Epic, Cerner, and Allscripts to avoid problems in the workflow. It’s also key that the AI supports billing rules by Medicare and private insurers to keep the money flowing.
Training and Support
For AI to work well, doctors and staff need training on how to watch over calls, handle AI alerts, and keep talking with patients. AI companies provide ongoing tech help to fix problems, update software, and add new features as needed.
More studies with many patients from different backgrounds are needed to prove that AI assistants like Dora R1 are safe and reliable for the US. Pilot programs that fit local rules and patients can help find out what works best.
Challenges include earning patients’ trust in AI, making sure older and underserved groups can use it, and knowing when a doctor must step in. Mixing AI with doctor help is probably the best way to go forward.
Working together, AI makers, doctors, and regulators need to write clear rules for using AI assistants safely in everyday care.
Medical managers and IT staff in the US should watch new AI clinical assistant technology closely. With more older patients and pressure on eye care, these tools could help manage patients safely, reliably, and cost-effectively while making workflows better and keeping healthcare running well over time.
Dora R1 is designed to conduct autonomous telemedicine follow-up assessments for cataract surgery patients, identifying and prioritizing those who need further clinical input, thereby expanding clinical capacity and improving patient triage post-surgery.
The accuracy was assessed by comparing Dora R1’s decisions on clinical symptoms and need for further review against those of supervising ophthalmologists in a sample of 202 patients following cataract surgery.
Dora R1 demonstrated an overall sensitivity of 94% and specificity of 86%, showing strong alignment with clinical decisions made by ophthalmologists.
Dora R1 showed moderate to strong agreement with clinicians, with kappa coefficients ranging from 0.758 to 0.970 across assessed clinical parameters, indicating high reliability in clinical decision-making.
Safety was affirmed as no patients incorrectly discharged by Dora R1 required additional follow-up after a callback. Unexpected management changes were minimal and coincided with clinician recommendations, indicating safe clinical use.
Feasibility was shown with 96.5% of calls completed autonomously by Dora R1, while usability and acceptability were generally positive, although some patients expressed concerns about the absence of human interaction in complex cases.
Patients generally accepted routine AI follow-ups but worried about the absence of a human component in managing complications, indicating sensitivity to the emotional and clinical nuances of AI communication.
Dora R1 reduced staff costs by approximately £35.18 per patient, highlighting important economic advantages in resource allocation for routine post-surgical follow-ups.
The study recommends further real-world implementation studies involving larger and more diverse patient populations across multiple Trusts to validate safety, effectiveness, and generalizability.
Dora R1 evaluated the clinical significance of five key symptoms commonly monitored post-cataract surgery to decide if patients required further clinical review or could be safely discharged.
Simbo is using AI agents to automate all phone related workflows. Connect now to know more.
Schedule AI Agents Demo Now© Since 2019, Simbo AI.
